| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1050028904 |
| P356 | DOI | 10.1038/SJ.LEU.2403640 |
| P698 | PubMed publication ID | 15674354 |
| P2093 | author name string | Kasai M | |
| Kodera Y | |||
| Kato S | |||
| Okamoto S | |||
| Matsushima T | |||
| Takahashi S | |||
| Fukuhara S | |||
| Nakai K | |||
| Hamajima N | |||
| Sakamaki H | |||
| Atsuta Y | |||
| Kanda Y | |||
| Tanosaki R | |||
| P2860 | cites work | Proposals for the classification of the myelodysplastic syndromes | Q28275931 |
| Estimation of failure probabilities in the presence of competing risks: new representations of old estimators | Q33594562 | ||
| A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome | Q34308142 | ||
| Allogeneic Stem-Cell Transplantation From Related and Unrelated Donors in Older Patients With Myeloid Leukemia | Q44405234 | ||
| Durable remissions of myelodysplastic syndrome and acute myeloid leukemia after reduced-intensity allografting | Q44547432 | ||
| Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. | Q54684597 | ||
| Relation of an Interleukin-10 Promoter Polymorphism to Graft-versus-Host Disease and Survival after Hematopoietic-Cell Transplantation | Q58814550 | ||
| Long-term follow-up of de novo myelodysplastic syndromes treated with intensive chemotherapy: incidence of long-term survivors and outcome of partial responders | Q73774661 | ||
| Bone marrow transplantation from HLA-identical siblings as first-line treatment in patients with myelodysplastic syndromes: early transplantation is associated with improved outcome. Chronic Leukemia Working Party of the European Group for Blood and | Q74266609 | ||
| Haematopoietic stem cell transplantation for patients with myelo-dysplastic syndromes and secondary acute myeloid leukaemias: a report on behalf of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT) | Q74346540 | ||
| Unrelated donor marrow transplantation for myelodysplastic syndromes: outcome analysis in 510 transplants facilitated by the National Marrow Donor Program | Q77725427 | ||
| Guidelines for the diagnosis and therapy of adult myelodysplastic syndromes | Q78833473 | ||
| P433 | issue | 3 | |
| P921 | main subject | myelodysplastic syndrome | Q954625 |
| P304 | page(s) | 396-401 | |
| P577 | publication date | 2005-03-01 | |
| P1433 | published in | Leukemia | Q6534498 |
| P1476 | title | Value of chemotherapy before allogeneic hematopoietic stem cell transplantation from an HLA-identical sibling donor for myelodysplastic syndrome | |
| P478 | volume | 19 |
| Q40276791 | Allogeneic Hematopoietic Stem Cell Transplantation Is Underutilized in Older Patients with Myelodysplastic Syndromes |
| Q36431041 | Allogeneic hematopoietic cell transplantation for MDS: for whom, when and how? |
| Q39092515 | Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel |
| Q37707098 | Better transplant outcome with pre-transplant marrow response after hypomethylating treatment in higher-risk MDS with excess blasts |
| Q36608689 | CD34-Selected Hematopoietic Stem Cell Transplants Conditioned with Myeloablative Regimens and Antithymocyte Globulin for Advanced Myelodysplastic Syndrome: Limited Graft-versus-Host Disease without Increased Relapse |
| Q43202931 | Comparative analysis of remission induction therapy for high-risk MDS and AML progressed from MDS in the MDS200 study of Japan Adult Leukemia Study Group |
| Q36063049 | Current status of allogeneic hematopoietic cell transplantation for MDS. |
| Q48587178 | Cytogenetic abnormalities in a series of 1,029 patients with primary myelodysplastic syndromes: a report from the US with a focus on some undefined single chromosomal abnormalities |
| Q48101262 | Decision analysis of allogeneic hematopoietic stem cell transplantation for patients with myelodysplastic syndrome stratified according to the revised International Prognostic Scoring System |
| Q36339459 | Five-group cytogenetic risk classification, monosomal karyotype, and outcome after hematopoietic cell transplantation for MDS or acute leukemia evolving from MDS. |
| Q82452939 | HLA-mismatched hematopoietic SCT without in vitro T-cell depletion for myelodysplastic syndrome |
| Q39805438 | Haploidentical transplant for myelodysplastic syndrome: registry-based comparison with identical sibling transplant. |
| Q33767314 | Hematopoietic stem cell transplantation for MDS. |
| Q37738524 | High-risk myelodysplastic syndromes: chemotherapy, transplantation, and beyond |
| Q35146316 | Impact of the revised International Prognostic Scoring System, cytogenetics and monosomal karyotype on outcome after allogeneic stem cell transplantation for myelodysplastic syndromes and secondary acute myeloid leukemia evolving from myelodysplasti |
| Q58103239 | Induction chemotherapy followed by allogeneic HCT versus upfront allogeneic HCT for advanced myelodysplastic syndrome: a propensity score matched analysis |
| Q90014004 | Infections in Myelodysplastic Syndrome in Relation to Stage and Therapy |
| Q41564676 | Influence of age on outcome after allogeneic hematopoietic cell transplantation: a single center study in patients aged ⩾60. |
| Q36806501 | Last marrow standing: bone marrow transplantation for acquired bone marrow failure conditions. |
| Q36683757 | Monosomal karyotype at the time of diagnosis or transplantation predicts outcomes of allogeneic hematopoietic cell transplantation in myelodysplastic syndrome |
| Q43451303 | Monosomal karyotype predicts poor survival after allogeneic stem cell transplantation in chromosome 7 abnormal myelodysplastic syndrome and secondary acute myeloid leukemia |
| Q38172875 | Novel therapeutic strategies using hypomethylating agents in the treatment of myelodysplastic syndrome |
| Q94527339 | Pre-transplant cytoreductive therapy can improve overall survival of patients with MDS-AML but not MDS-EB2 receiving HLA-matched sibling donor peripheral blood stem cell transplantation |
| Q90209225 | Pre-transplant hypomethylating agents do not influence post-transplant survival in myelodysplastic syndrome |
| Q42233134 | Prediction of infectious complications by the combination of plasma procalcitonin level and localized infection before allogeneic hematopoietic cell transplantation |
| Q87415721 | Prediction of transplant-related complications by C-reactive protein levels before hematopoietic SCT |
| Q36036263 | Pretransplantation therapy with azacitidine vs induction chemotherapy and posttransplantation outcome in patients with MDS. |
| Q37389675 | Prognostic pre-transplant factors in myelodysplastic syndromes primarily treated by high dose allogeneic hematopoietic stem cell transplantation: a retrospective study of the MDS subcommittee of the CMWP of the EBMT. |
| Q36920394 | Review of stem-cell transplantation for myelodysplastic syndromes in older patients in the context of the Decision Memo for Allogeneic Hematopoietic Stem Cell Transplantation for Myelodysplastic Syndrome emanating from the Centers for Medicare and M |
| Q34549306 | Role and timing of hematopoietic cell transplantation for myelodysplastic syndrome |
| Q36039542 | Soluble DNAM-1, as a Predictive Biomarker for Acute Graft-Versus-Host Disease |
| Q52897534 | The bridge treatment selected at the decision for transplantation did not affect the outcomes in patients with MDS. |
| Q37404489 | The evolution of hematopoietic SCT in myelodysplastic syndrome |
| Q79552813 | Total body irradiation and granulocyte colony-stimulating factor-combined high-dose cytarabine as a conditioning regimen in allogeneic hematopoietic stem cell transplantation for advanced myelodysplastic syndrome: a single-institute experience |
| Q37600407 | Transplantation for myelodysplastic syndromes 2013. |
| Q56889073 | Unification of hematopoietic stem cell transplantation registries in Japan and establishment of the TRUMP System |
| Q34166581 | Value of allogeneic versus autologous stem cell transplantation and chemotherapy in patients with myelodysplastic syndromes and secondary acute myeloid leukemia. Final results of a prospective randomized European Intergroup Trial |
| Q38148983 | When to transplant MDS, and what to do when transplant fails |
Search more.